RxDoctor Payments Data

Patricia Williamson, NP

Primary Care · Bowling Green, VANPI 1285334078

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.9% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Novo Nordisk at 28.9% of the total.

$608in general payments, 2019–2025

Across 29 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$176
  • Organon$86
  • Amgen$68
  • AstraZeneca$57
  • Lilly USA, LLC$50
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$47
  • plus $125 from 5 others

What the payments were for

  • Food & beverage$58997%
  • Education$193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$608 in reported general payments places this provider in the 55th percentile of 142 primary care providers in Virginia.

See all primary care providers in Virginia

Medicare billing

Part B allowed, 2024
$2,788
Medicare patients
34
Services billed
65

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept13$97,253
OzempicSemaglutide74$81,502
TrulicityDulaglutide55$51,555
FarxigaDapagliflozin Propanediol34$48,006
JardianceEmpagliflozin31$41,261
EliquisApixaban19$27,162
Repatha SyringeEvolocumab31$22,626
CaplytaLumateperone Tosylate12$20,050
WegovySemaglutide13$18,053
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$15,664
SymbicortBudesonide/Formoterol Fumarate17$7,656
Spiriva HandihalerTiotropium Bromide13$6,330
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,407
ShingrixVaricella-Zoster Ge/As01b/Pf19$3,993
Lidocaine26$3,755

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$176$99,55587 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$57$71,32664 claims
Lilly USA, LLCTrulicity$50$51,55555 claims
Boehringer IngelheimJardiance$19$41,26131 claims
PfizerEliquis$18$27,16219 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$47$20,05012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 142 primary care providers in Virginia.

Other primary care in Bowling Green

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →